PMID- 17845588
OWN - NLM
STAT- MEDLINE
DCOM- 20080226
LR  - 20151119
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 62
IP  - 10
DP  - 2007 Oct
TI  - CD-sens and clinical changes during withdrawal of Xolair after 6 years of 
      treatment.
PG  - 1175-81
AB  - BACKGROUND: Many clinical trials with omalizumab, Xolair, have been reported but 
      the treatment period has always been short, i.e. <12 months. After withdrawal, 
      the clinical symptoms tend to return. A group of patients who stopped treatment 
      after approx. 6 years allowed studies of the long-term effects of Xolair. 
      METHODS: The patient's cat or mite allergen sensitivity was quantitated as 
      basophil allergen threshold sensitivity, CD-sens, and immunoglobulin E (IgE) and 
      IgE- and IgG4-antibodies were determined before start and during treatment 
      withdrawal. Asthma severity was evaluated from forced expiratory volume (FEV), 
      peak expiratory flow (PEF) and a questionnaire. RESULTS: At 6-14 months without 
      Xolair 13 of the 18 cat and mite allergic asthmatics had either improved or 
      remained the same as on treatment. Most of the patients were in a stable clinical 
      condition reporting high quality of life, no increased nightly asthma attacks, no 
      emergency visits as well as little or no increase in medication. The CD-sens to 
      cat showed a peak 4 months after withdrawal but then decreased to levels below 
      those of untreated patients with allergic asthma and at 12 months six of 14 had 
      nonreactive basophils. Cat IgG4 antibody levels were higher than in cat allergics 
      in general. CONCLUSION: Most of the patients 12-14 months had, after closing of 
      6-year Xolair treatment, a surprisingly mild asthma. Interestingly, and probably 
      contributing to the clinical results, a downregulation of basophil, and 
      presumably also mast cell, reactivity, was seen.
FAU - Nopp, A
AU  - Nopp A
AD  - Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska 
      Institute, Stockholm, Sweden.
FAU - Johansson, S G O
AU  - Johansson SG
FAU - Ankerst, J
AU  - Ankerst J
FAU - Palmqvist, M
AU  - Palmqvist M
FAU - Oman, H
AU  - Oman H
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Allergens/immunology
MH  - Anti-Asthmatic Agents/administration & dosage
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/*immunology
MH  - Basophils/immunology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Omalizumab
MH  - Rhinitis, Allergic, Seasonal/blood/drug therapy/immunology
MH  - Substance Withdrawal Syndrome/*immunology
MH  - Treatment Outcome
MH  - *Withholding Treatment
EDAT- 2007/09/12 09:00
MHDA- 2008/02/27 09:00
CRDT- 2007/09/12 09:00
PHST- 2007/09/12 09:00 [pubmed]
PHST- 2008/02/27 09:00 [medline]
PHST- 2007/09/12 09:00 [entrez]
AID - ALL1476 [pii]
AID - 10.1111/j.1398-9995.2007.01476.x [doi]
PST - ppublish
SO  - Allergy. 2007 Oct;62(10):1175-81. doi: 10.1111/j.1398-9995.2007.01476.x.